# Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

> **NCT06376162** · PHASE1 · RECRUITING · sponsor: **PedAL BCU, LLC** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed/Refractory KMT2A-r Acute Leukemia
- Relapsed/Refractory NUP98-r Acute Leukemia
- Relapsed/Refractory NPM1-m Acute Leukemia

## Interventions

- **DRUG:** Ziftomenib
- **DRUG:** Cytarabine
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06376162
- **Lead sponsor:** PedAL BCU, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06376162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06376162, "Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06376162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*